The Chinese research team reported in the lancet, a British Medical Journal, on Tuesday that they had conducted a phase 1 clinical trial of a new coronavirus vaccine, which showed that the vaccine was safe and could induce a rapid immune response.

The clinical trial was carried out by a team led by academician Chen Wei of the Institute of bioengineering, Academy of military medicine, Academy of Military Sciences*binant coronavirus vaccine with adenovirus vector. In the experiment, the team recruited 108 healthy adult volunteers, aged between 18 and 60. The volunteers were divided into different groups and vaccinated with different doses.

The report said that within 28 days after vaccination, the vaccine showed good tolerance in different dose groups and did not cause serious adverse reactions.

In a press release released by the lancet, Chen Wei said that phase 1 clinical trials showed that vaccination with the adenovirus vector recombinant new coronavirus vaccine could induce the production of virus-specific antibodies and T cells within 14 days, "these results represent an important milestone* about relevant achievements, and the development of new coronavirus vaccine will face unprecedented challenges, and the ability to trigger an immune response does not necessarily mean that the vaccine can protect people from new coronavirus infection, The results "show a good prospect for the development of the new coronavirus vaccine, but we still have a long way to go before the vaccine reaches the stage for all people to use.".

The report said that the main limitations of this clinical trial include small sample size, short trial period, lack of randomized control group, etc., so further tests are needed to verify.

According to the lancet, developing an effective vaccine is a long-term solution for the prevention and control of new coronavirus outbreaks* vaccines are under development in the world.